» Articles » PMID: 35486722

High-resolution Profiling of MHC II Peptide Presentation Capacity Reveals SARS-CoV-2 CD4 T Cell Targets and Mechanisms of Immune Escape

Abstract

Understanding peptide presentation by specific MHC alleles is fundamental for controlling physiological functions of T cells and harnessing them for therapeutic use. However, commonly used in silico predictions and mass spectroscopy have their limitations in precision, sensitivity, and throughput, particularly for MHC class II. Here, we present MEDi, a novel mammalian epitope display that allows an unbiased, affordable, high-resolution mapping of MHC peptide presentation capacity. Our platform provides a detailed picture by testing every antigen-derived peptide and is scalable to all the MHC II alleles. Given the urgent need to understand immune evasion for formulating effective responses to threats such as SARS-CoV-2, we provide a comprehensive analysis of the presentability of all SARS-CoV-2 peptides in the context of several HLA class II alleles. We show that several mutations arising in viral strains expanding globally resulted in reduced peptide presentability by multiple HLA class II alleles, while some increased it, suggesting alteration of MHC II presentation landscapes as a possible immune escape mechanism.

Citing Articles

Circular RNAs in the pathogenesis of SARS-CoV-2: potential diagnostic biomarkers and therapeutic targets.

Wu J, Li L, Xu W, Xia X, Wu Y Funct Integr Genomics. 2025; 25(1):4.

PMID: 39745517 DOI: 10.1007/s10142-024-01509-6.


MMPred: a tool to predict peptide mimicry events in MHC class II recognition.

Guerri F, Junet V, Farres J, Daura X Front Genet. 2024; 15:1500684.

PMID: 39722794 PMC: 11669352. DOI: 10.3389/fgene.2024.1500684.


Circulating tumor-reactive KIRCD8 T cells suppress anti-tumor immunity in patients with melanoma.

Lu B, Lucca L, Lewis W, Wang J, Nogueira C, Heer S Nat Immunol. 2024; 26(1):82-91.

PMID: 39609626 DOI: 10.1038/s41590-024-02023-4.


Bioinformatic elucidation of conserved epitopes to design a potential vaccine candidate against existing and emerging SARS-CoV-2 variants of concern.

Rastogi A, Gautam S, Kumar M Heliyon. 2024; 10(15):e35129.

PMID: 39157328 PMC: 11328099. DOI: 10.1016/j.heliyon.2024.e35129.


To stay or not to stay intact as an allergen: the endolysosomal degradation assay used as tool to analyze protein immunogenicity and cell epitopes.

Oztemiz Topcu E, Gadermaier G Front Allergy. 2024; 5:1440360.

PMID: 39071040 PMC: 11272489. DOI: 10.3389/falgy.2024.1440360.


References
1.
Juno J, Tan H, Lee W, Reynaldi A, Kelly H, Wragg K . Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020; 26(9):1428-1434. DOI: 10.1038/s41591-020-0995-0. View

2.
Zhang T, He X, Tsang T, Harris D . SING: a novel strategy for identifying tumor-specific, CTL-recognized tumor antigens. FASEB J. 2004; 18(3):600-2. DOI: 10.1096/fj.03-0881fje. View

3.
Reynisson B, Barra C, Kaabinejadian S, Hildebrand W, Peters B, Nielsen M . Improved Prediction of MHC II Antigen Presentation through Integration and Motif Deconvolution of Mass Spectrometry MHC Eluted Ligand Data. J Proteome Res. 2020; 19(6):2304-2315. DOI: 10.1021/acs.jproteome.9b00874. View

4.
Reynolds C, Pade C, Gibbons J, Butler D, Otter A, Menacho K . Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021; . PMC: 8168614. DOI: 10.1126/science.abh1282. View

5.
Oldford S, Robb J, Codner D, Gadag V, Watson P, Drover S . Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol. 2006; 18(11):1591-602. DOI: 10.1093/intimm/dxl092. View